Thomas Stehlé

@tstehle.bsky.social

Néphrologue HU Henri Mondor

Urea may be a cost-effective alternative to tolvaptan for 🏥 SIADH patients. In a retrospective 📑 (n=537) both achieved similar correction of HypoNa (>130 mmol/L) while tolvaptan acted faster but caused more overcorrection & was substantially more 💵 🔗https://doi.org/10.1093/ndt/gfag165

Urea vs. tolvaptan for hospitalized patients with SIADH

AbstractRationale. Hyponatremia is the most common electrolyte disorder found in hospitalized patients and is associated with an increased mortality. Urea

doi.org